Corona Remedies Limited – IPO
Corona Remedies Limited – IPO Details
| IPO Date | December 8, 2025 to December 10, 2025 |
| Listing Date | December 15, 2025 |
| Face Value | ₹ 10 / Share |
| Price Band | ₹ 1008 to ₹ 1062 / Share |
| Lot Size | 14 Shares |
| Total Issue Size | 61,71,101 shares (Aggregating up to ₹655.37 Cr) |
| Fresh Issue | |
| Offer for Sale | |
| Employee Discount | ₹54.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 6,11,60,088 shares |
| Share holding post issue | 6,11,60,088 shares |
| Market Maker portion |
Corona Remedies Limited Timeline (Tentative Schedule)
Corona Remedies Limited IPO opens on December 8, 2025, and closes on December 10, 2025.
| IPO Open Date | December 8, 2025 |
| IPO Close Date | December 10, 2025 |
| Basis of Allotment | December 11, 2025 |
| Initiation of Refunds | December 12, 2025 |
| Credit of Shares to Demat | December 12, 2025 |
| Listing Date | December 15, 2025 |
| Cut-off time for UPI mandate confirmation | December 10, 2025 |
Corona Remedies Limited IPO Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | Rs.14,868 |
| Retail (Max) | 13 | 182 | Rs.193,284 |
| S-HNI (Min) | 14 | 196 | Rs.208,152 |
| S-HNI (Max) | 67 | 938 | Rs.996,156 |
| B-HNI (Min) | 68 | 952 | Rs.1,011,024 |
| HNI (Min) |
Corona Remedies Limited IPO Promoter Holding
| Share Holding Pre Issue | 72.50% |
| Share Holding Post Issue |
Corona Remedies Limited IPO Reservation
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not less than 50% |
|
| NII (HNI) Shares Offered | Not more than 15% |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not more than 35% |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
Corona Remedies Limited IPO Anchor Investors Details
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
About Corona Remedies Limited
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.
Competitive Strength:
- Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
- Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
- Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
- Qualified, experienced and entrepreneurial management team supported by marquee investors.
Key Performance Indicator
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| Debt/Equity | 0.10 |
| RoNW | 24.65% |
| P/BV | 10.71 |
| PAT Margin (%) | 12.49% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 24.43 | 30.21 |
| P/E (x) | 43.47 | 35.15 |
Note:
- The Pre IPO EPS is calculated based on Pre-IPO shareholding as on the date of RHP and the latest FY earnings as of March 31, 2025, which is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of June 30, 2025, which is available in RHP.
Objects of the Issue (Corona Remedies Limited IPO Objectives)
Corona Remedies Limited Contact Details
Corona Remedies Ltd. CORONA House, C – Mondeal Business Park Near Gurudwara S. G. Highway Thaltej Ahmedabad, Gujarat, 380059 Phone: +91 79 4023 3000 Email: [email protected] Website: https://www.coronaremedies.com/ |
Corona Remedies Limited IPO Registrar
Bigshare Services Pvt.Ltd. Phone: +91-22-6263 8200 Email: [email protected] |